All In Biotech

Drug Trial Radar · NCT04566328

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,450 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,450

Planned (sponsor's estimate)

Start

Feb 24, 2021

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
ECOG-ACRIN Cancer Research GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Sep 28, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.

Conditions

  • Plasma Cell Myeloma
  • RISS Stage I Plasma Cell Myeloma
  • RISS Stage II Plasma Cell Myeloma

Interventions

  • BortezomibDrug

    Given SC

  • Daratumumab and Hyaluronidase-fihjBiological

    Given SC

  • DexamethasoneDrug

    Given PO

  • LenalidomideDrug

    Given PO

  • Quality-of-Life AssessmentOther

    Ancillary studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Consolidation overall survivalTime frame: Time from Step 2 randomization at the start of consolidation to death or to the date last known alive, assessed up to 15 years

Locations

647 sites in 2 countries. Site status is shown where the registry gives one.

  • Anchorage Associates in Radiation Medicine

    Anchorage, Alaska · Suspended

  • Anchorage Radiation Therapy Center

    Anchorage, Alaska · Suspended

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska · Suspended

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska · Suspended

  • Alaska Women's Cancer Care

    Anchorage, Alaska · Suspended

  • Anchorage Oncology Centre

    Anchorage, Alaska · Suspended

  • Katmai Oncology Group

    Anchorage, Alaska · Suspended

  • Providence Alaska Medical Center

    Anchorage, Alaska · Suspended

  • Cancer Center at Saint Joseph's

    Phoenix, Arizona · Recruiting

  • University of Arizona Cancer Center-Orange Grove Campus

    Tucson, Arizona · Suspended

  • Banner University Medical Center - Tucson

    Tucson, Arizona · Suspended

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona · Suspended

  • Mercy Hospital Fort Smith

    Fort Smith, Arkansas · Recruiting

  • CHI Saint Vincent Cancer Center Hot Springs

    Hot Springs, Arkansas · Suspended

  • CARTI Cancer Center

    Little Rock, Arkansas · Recruiting

  • John L McClellan Memorial Veterans Hospital

    Little Rock, Arkansas · Suspended

  • Mission Hope Medical Oncology - Arroyo Grande

    Arroyo Grande, California · Recruiting

  • Sutter Auburn Faith Hospital

    Auburn, California · Suspended

  • Sutter Cancer Centers Radiation Oncology Services-Auburn

    Auburn, California · Suspended

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California · Suspended

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California · Suspended

  • Mills-Peninsula Medical Center

    Burlingame, California · Suspended

  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park

    Cameron Park, California · Suspended

  • Mercy Cancer Center - Carmichael

    Carmichael, California · Recruiting

  • Mercy San Juan Medical Center

    Carmichael, California · Recruiting

  • Eden Hospital Medical Center

    Castro Valley, California · Suspended

  • Sutter Davis Hospital

    Davis, California · Suspended

  • Mercy Cancer Center - Elk Grove

    Elk Grove, California · Recruiting

  • Palo Alto Medical Foundation-Fremont

    Fremont, California · Suspended

  • Washington Health

    Fremont, California · Recruiting

  • Mercy Cancer Center

    Merced, California · Recruiting

  • Memorial Medical Center

    Modesto, California · Suspended

  • Palo Alto Medical Foundation-Camino Division

    Mountain View, California · Suspended

  • Palo Alto Medical Foundation-Gynecologic Oncology

    Mountain View, California · Suspended

  • Sutter Cancer Research Consortium

    Novato, California · Suspended

  • Palo Alto Medical Foundation Health Care

    Palo Alto, California · Suspended

  • Mercy Cancer Center - Rocklin

    Rocklin, California · Recruiting

  • Sutter Cancer Centers Radiation Oncology Services-Roseville

    Roseville, California · Suspended

  • Sutter Roseville Medical Center

    Roseville, California · Suspended

  • Mercy Cancer Center - Sacramento

    Sacramento, California · Recruiting

Showing 40 of 647 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.